Mosunetuzumab
- Generic Name
- Mosunetuzumab
- Brand Names
- Lunsumio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1905409-39-3
- Unique Ingredient Identifier
- LDJ89SS0YG
- Background
Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as rituximab, in co...
- Indication
Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Associated Conditions
- Relapsed or Refractory Follicular Lymphoma
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath